AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECG TM software platform has ...

Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse pulsed field ablation (PFA) system and Farapoint PFA ...

A significant proportion of patients undergoing atrial fibrillation (AF ... or one episode of persistent AF in the past 6 months (37.2% women; median left ventricular ejection fraction, 59%).

Freedom from recurrent atrial flutter was 97.2%. Detailed analysis of the full ICM data revealed freedom from AA ≥30 seconds in 52.0%, and no episode exceeded 24 hours in 94.0% of this PerAF cohort.

CHICAGO — Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic ... 2.2-3.5), a composite kidney outcome (aHR = 2; 95% CI, 1.4-2.7) and all-cause death (aHR ...